Eli Lilly and Company
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LLY research report →
About the company
Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.
- CEO
- David A. Ricks
- IPO
- 1972
- Employees
- 47,000
- HQ
- Indianapolis, IN, US
Price Chart
- Market Cap
- $1.06T
- P/E
- 39.73
- P/S
- 14.63
- P/B
- 32.18
- EV/EBITDA
- 32.73
- Div Yield
- 0.58%
- Gross Margin
- 83.51%
- Op Margin
- 45.87%
- Net Margin
- 34.98%
- ROE
- 101.30%
- ROIC
- 32.06%
- Revenue
- $65.18B · 44.70%
- Net Income
- $20.64B · 94.88%
- EPS
- $23.00 · 95.58%
- Op Income
- $29.70B
- FCF YoY
- 2065.58%
- 52W High
- $1182.73
- 52W Low
- $623.78
- 50D MA
- $1000.66
- 200D MA
- $960.42
- Beta
- 0.52
- Avg Volume
- 3.24M
Get TickerSpark's AI analysis on LLY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 15, 26 | Sulzberger Gabrielle | other | 4.39 |
| Jun 15, 26 | LUCIANO JUAN R | other | 14.094 |
| Jun 15, 26 | Fyrwald J Erik | other | 8.781 |
| Jun 15, 26 | Alvarez Ralph | other | 10.995 |
| Jun 10, 26 | Yuffa Ilya | sell | 2,500 |
| May 18, 26 | Sulzberger Gabrielle | other | 5.018 |
| May 18, 26 | LUCIANO JUAN R | other | 16.109 |
| May 18, 26 | Fyrwald J Erik | other | 10.036 |
| May 18, 26 | Alvarez Ralph | other | 12.566 |
| May 6, 26 | LILLY ENDOWMENT INC | sell | 13,620 |
Our LLY coverage
Recent articles, reports, and earnings notes.
Eli Lilly (LLY): Incretin Growth Still Drives the Story
Eli Lilly is delivering exceptional revenue and EPS growth, led by Mounjaro and Zepbound, while raising 2026 guidance again. The stock is expensive, but the franchise momentum and pipeline breadth keep the long-term case intact.
The GLP-1 trade is becoming a market-share war, not a rising-tide story
Investors still talk about obesity drugs like a category ETF, but the evidence now points to a leadership trade. Eli Lilly is widening the gap with stronger execution, better prescription momentum, and a more threatening pipeline just as Novo Nordisk faces pricing pressure and a weaker growth profile.
Top Obesity Drugs Stocks: Our 3 Picks for 2026
Lilly, Novo Nordisk, and Hims & Hers offer three different ways to invest in obesity drugs, with Lilly ranking highest on overall quality and execution.
Want a deeper read on LLY?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Similar companies
Peers in the same neighborhood.